Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.76M | $30.0M | $37.1M | $39.7M | $55.4M | $56.2M | $50.3M | $53.4M | $54.4M | $65.3M |
| Revenue growth | — | 344.3% | 23.6% | 7.0% | 39.6% | 1.5% | -10.5% | 6.0% | 2.0% | 19.9% |
| Gross profit | $601K | $1.96M | $2.41M | $3.66M | $8.06M | $8.33M | $5.96M | $4.35M | $4.31M | $7.90M |
| Gross margin | 8.9% | 6.5% | 6.5% | 9.2% | 14.5% | 14.8% | 11.8% | 8.1% | 7.9% | 12.1% |
| Operating income | -$203K | -$4.87M | -$1.23M | -$256K | $2.71M | -$4.53M | -$7.47M | -$21.8M | -$15.5M | -$16.7M |
| Operating margin | -3.0% | -16.2% | -3.3% | -0.6% | 4.9% | -8.1% | -14.8% | -40.9% | -28.6% | -25.6% |
| Net income | -$601K | -$6.21M | -$9.06M | -$3.30M | $821K | -$7.96M | -$13.8M | -$18.5M | -$16.2M | -$19.1M |
| Net margin | -8.9% | -20.7% | -24.4% | -8.3% | 1.5% | -14.2% | -27.5% | -34.7% | -29.7% | -29.3% |
| EPS (diluted) | $80,741.00 | -$0.49 | -$0.68 | -$0.25 | $0.06 | -$23.74 | -$33.16 | -$2.15 | -$1.17 | -$0.63 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.13M | -$8.76M | -$1.56M | -$4.79M | -$11.5M | -$7.10M | -$14.9M | -$15.6M | -$7.72M | -$8.45M |
| Capital expenditures | $12.8K | $55.3K | $503K | — | $118K | $581K | $74.2K | $1.31M | $418K | $55.7K |
| Free cash flow | -$2.14M | -$8.82M | -$2.06M | — | -$11.6M | -$7.68M | -$14.9M | -$16.9M | -$8.14M | -$8.50M |
| Share buybacks | — | — | — | — | $200K | $377K | — | $100K | $0.00 | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $717K | $783K | $864K | $38.5K | $628K | $286K | $20.7M | $3.83M | $315K | $716K |
| Total assets | $3.12M | $10.7M | $20.7M | $23.9M | $43.8M | $49.4M | $68.0M | $66.0M | $54.3M | $65.5M |
| Total liabilities | $4.87M | $13.7M | $24.0M | $30.3M | $48.0M | $45.0M | $28.4M | $30.0M | $29.8M | $47.1M |
| Long-term debt | — | — | $146K | $0.00 | $10.8M | $17.9M | $5.02M | $4.61M | $4.11M | $3.78M |
| Shareholders' equity | -$1.75M | -$3.03M | -$3.32M | -$6.46M | -$4.16M | $4.38M | $39.3M | $36.0M | $24.5M | $18.4M |
| Retained earnings | -$1.00M | -$7.21M | -$16.3M | -$19.6M | -$18.8M | -$34.3M | -$66.2M | -$91.6M | -$114M | -$133M |
| Shares (wtd avg diluted) | 126M | 12.8M | 13.3M | 13.3M | 13.3M | 657K | 1.93M | 12.0M | 19.1M | 30.3M |
Every figure is extracted from Cosmos Health Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.